Host |
Mouse |
Klon |
DC-10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zytomed Systems GmbH |
DC-10 |
0.5 ml |
Concentrate |
RUO |
MSK016-05 |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human breast cancer PMC 42 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
DC10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2044ML |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Human breast cancer PMC 42 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
DC10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2044MP |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human breast cancer PMC 42 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
DC10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2044MS |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human breast cancer PMC 42 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
DC10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2044MT |
-
|
Host |
Mouse |
Klon |
ZM205 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human KRT18 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
ZM205 |
1.0 ml |
Concentrate |
CE/IVD |
Z2541ML |
-
|
Host |
Mouse |
Klon |
ZM205 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human KRT18 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
ZM205 |
7 ml |
Ready-to-use |
CE/IVD |
Z2541MP |
-
|
Host |
Mouse |
Klon |
ZM205 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human KRT18 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
ZM205 |
0.5 ml |
Concentrate |
CE/IVD |
Z2541MS |
-
|
Host |
Mouse |
Klon |
ZM205 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human KRT18 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zeta Corporation |
ZM205 |
0.1 ml |
Concentrate |
CE/IVD |
Z2541MT |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Colon, Skin |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
Cytokeratin 18 (CK18)
|
Biocare Medical |
DC10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3061A |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Colon, Skin |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
Cytokeratin 18 (CK18)
|
Biocare Medical |
DC10 |
1 ml |
Concentrate |
CE/IVD |
ACI3061C |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Colon, Skin |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
Cytokeratin 18 (CK18)
|
Biocare Medical |
DC10 |
6 ml |
Ready-to-use |
CE/IVD |
API3061AA |
-
|
Host |
Mouse |
Klon |
BA17 |
Format |
Purified |
Methode |
F, P, WB |
Vorbehandlung |
Trypsin, Pronase |
Positivkontrolle |
Normal Breast |
Verdünnung |
1:50 - 1:100 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Mammary organoids |
Cytokeratin 19
|
Zytomed Systems GmbH |
BA17 |
200 µg |
Purified |
RUO |
603-2176 |
-
|
Host |
Mouse |
Klon |
BA17 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
1.0 ml |
Concentrate |
CE/IVD |
Z2134ML |
-
|
Host |
Mouse |
Klon |
BA17 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
7 ml |
Ready-to-use |
CE/IVD |
Z2134MP |
-
|
Host |
Mouse |
Klon |
BA17 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
0.5 ml |
Concentrate |
CE/IVD |
Z2134MS |
-
|
Host |
Mouse |
Klon |
BA17 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Detergent-insoluble extract of human mammary epithelial organoids |
Lokalisation |
Cytoplasm |
Cytokeratin 19
|
Zeta Corporation |
BA17 |
0.1 ml |
Concentrate |
CE/IVD |
Z2134MT |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
proteolytic |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
1 ml |
Concentrate |
CE/IVD |
MOB123 |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
proteolytic |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB123-01 |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
proteolytic |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB123-05 |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
proteolytic |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Diagnostic Biosystems |
Ks20.8 |
6 ml |
Ready-to-use |
CE/IVD |
PDM049 |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Semi-purified human cytokeratin preparation |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
1ml |
Concentrate |
CE/IVD |
Z2065ML |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Semi-purified human cytokeratin preparation |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2065MP |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Semi-purified human cytokeratin preparation |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2065MS |
-
|
Host |
Mouse |
Klon |
Ks20.8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Semi-purified human cytokeratin preparation |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
Ks20.8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2065MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM42 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
1 ml |
Concentrate |
CE/IVD |
Z2349ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM42 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
7 ml |
Ready-to-use |
CE/IVD |
Z2349MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM42 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
0.5 ml |
Concentrate |
CE/IVD |
Z2349MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM42 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human KRT20 protein fragment (around aa 196-323) |
Lokalisation |
Cytoplasm |
Cytokeratin 20
|
Zeta Corporation |
ZM42 |
0.1 ml |
Concentrate |
CE/IVD |
Z2349MT |
-
|
Host |
Mouse |
Klon |
AE1+AE3+5D3 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Squamous lung carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic |
Cytokeratin AE1+AE3 + CK 5/18
|
Diagnostic Biosystems |
AE1+AE3+5D3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM601 |
-
|
Host |
Mouse |
Klon |
34βE12 |
Format |
ready-to-use |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Verdünnung |
--- |
Isotyp |
IgG1 /κ |
Verdünnung |
HMW CK [34βE12] |
Lokalisation |
Cytoplasmic |
Cytokeratin HMW [34βE12]
|
Biocare Medical |
34βE12 |
6 ml |
ready-to-use |
CE/IVD |
AVI127G |
-
|
Host |
Mouse |
Klon |
XM26+LL002+BC4A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Prostatic intraepithelial neoplasia PIN |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1+IgG3+IgG2a |
Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin HMW & p63 Cocktail (Basal Cell Cocktail)
|
Biocare Medical |
XM26+LL002+BC4A4 |
1 ml |
Concentrate |
CE/IVD |
CM210C |
-
|
Host |
Mouse |
Klon |
XM26+LL002+BC4A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 |
Positivkontrolle |
Prostatic intraepithelial neoplasia PIN |
Verdünnung |
- |
Isotyp |
Mouse IgG1+IgG3+IgG2a |
Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin HMW & p63 Cocktail (Basal Cell Cocktail)
|
Biocare Medical |
XM26+LL002+BC4A4 |
6 ml |
Ready-to-use |
CE/IVD |
PM210AA |
-
|
Host |
Mouse |
Klon |
34βE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Solubilized keratin extracted from human stratum corneum |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
1.0 ml |
Concentrate |
CE/IVD |
Z2019ML |
-
|
Host |
Mouse |
Klon |
34βE12 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Solubilized keratin extracted from human stratum corneum |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2019MP |
-
|
Host |
Mouse |
Klon |
34βE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Solubilized keratin extracted from human stratum corneum |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2019MS |
-
|
Host |
Mouse |
Klon |
34βE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Solubilized keratin extracted from human stratum corneum |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, HMW
|
Zeta Corporation |
34βE12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2019MT |
-
|
Host |
Mouse |
Klon |
AE1/AE3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG2a /κ |
Verdünnung |
Human epidermal keratin |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
1.0 ml |
Concentrate |
CE/IVD |
Z2061ML |
-
|
Host |
Mouse |
Klon |
AE1/AE3 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
- |
Isotyp |
IgG1 /κ + IgG2a /κ |
Verdünnung |
Human epidermal keratin |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2061MP |
-
|
Host |
Mouse |
Klon |
AE1/AE3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG2a /κ |
Verdünnung |
Human epidermal keratin |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2061MS |
-
|
Host |
Mouse |
Klon |
AE1/AE3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG2a /κ |
Verdünnung |
Human epidermal keratin |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
AE1/AE3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2061MT |
-
|
Host |
Mouse |
Klon |
OSCAR |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:25-100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
1.0 ml |
Concentrate |
CE/IVD |
Z2539ML |
-
|
Host |
Mouse |
Klon |
OSCAR |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
7 ml |
Ready-to-use |
CE/IVD |
Z2539MP |
-
|
Host |
Mouse |
Klon |
OSCAR |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:25-100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
0.5 ml |
Concentrate |
CE/IVD |
Z2539MS |
-
|
Host |
Mouse |
Klon |
OSCAR |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma, prostate. |
Verdünnung |
1:25-100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Crude cytokeratin extract prepared from RT-4 and MCF-7 cells |
Lokalisation |
Membranous and Cytoplasm |
Cytokeratin, Pan
|
Zeta Corporation |
OSCAR |
0.1 ml |
Concentrate |
CE/IVD |
Z2539MT |
-
|
Host |
Mouse |
Klon |
DDG9+CCH2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG2a+IgG1 |
Verdünnung |
Cytomegalovirus infected cell lysate |
Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
0.5 ml |
Concentrate |
RUO |
MOB049-05R |
-
|
Host |
Mouse |
Klon |
DDG9+CCH2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG2a+IgG1 |
Verdünnung |
Cytomegalovirus infected cell lysate |
Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
1 ml |
Concentrate |
RUO |
MOB049R |
-
|
Host |
Mouse |
Klon |
DDG9+CCH2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG2a+IgG1 |
Verdünnung |
Cytomegalovirus infected cell lysate |
Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
0.1 ml |
Concentrate |
RUO |
MOB049R-01 |
-
|
Host |
Mouse |
Klon |
DDG9+CCH2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Infected Lung |
Verdünnung |
- |
Isotyp |
Mouse IgG2a-kappa/1-kappa |
Verdünnung |
Cytomegalovirus infected cell lysate |
Lokalisation |
Nucleus |
Cytomegalovirus (CMV Cocktail)
|
Diagnostic Biosystems |
DDG9+CCH2 |
6 ml |
Ready-to-use |
RUO |
PDM075R |
-
|
Host |
Mouse |
Format |
Purified |
Methode |
P, IF, EL |
Isotyp |
Mouse IgG1 |
Cytomegalovirus (CMV) (gH)
|
Zytomed Systems GmbH |
- |
100 µg |
Purified |
RUO |
603-2188 |
-
|